title: Addition of bevacizumab to temsirolimus in kidney cancer patients.
abstract: Treatment of metastatic kidney cancer has changed dramatically in the past years with the use of VEGF-targeted therapies and mTOR inhibitors. However, resistance occurs. We report here two cases of patients who benefited, both on disease control and side effects, from the addition of bevacizumab to temsirolimus, after progression on the mTOR inhibitor alone.
authors.affiliation: Centre Léon Bérard, Department of Medical Oncology, Lyon, France.
authors.forename: H
authors.initials: H
authors.lastname: Boyle
authors.forename: S
authors.initials: S
authors.lastname: Négrier